Pipeline
PRODUCT PIPELINE
Avirmax is at the preclinical stage of biotherapeutics development using our rAAV delivery system. Currently, we are developing multiple candidate rAAV vectors. The following are examples of our product pipelines under development.
Preclinical Studies
Clinical Investigatons
Indication
COV DecoyRTM
AVMX-801
COVID-19
Cardiovascular
AVMX-810
High Blood Pressure
iCare-NIU
AVMX-107
AVMX-108
Not Disclosed
iCare-CNV
AVMX-100
AVMX-116
AVMX-110
AVMX-112
Not Disclosed
Genetic disease
AVMX-901
Not Disclosed
Evaluation
Studies
Indication
nAMD, PCV, RVO, DME
DME, DMR
iCare CNV
DME, nAMD, PCV, RVO,
iCare-NIU
uvCNV, UMO
iCare RGC
Glaucoma
Production
AMD = Age-Related Macular Degeneration
CNV = Choroidal Neovascularization
DME = Diabetic Macular Edema
DMR = Diabetic Macular Retinopathy
PCV = Polypoidal Choroidal Vasculopathy
RVO = Retinal Vein Occlusion
UMO = Uveitic Macular Oedema
Indication
nAMD, PCV, RVO, DME
DME, DMR
iCare CNV
DME, nAMD, PCV, RVO,
iCare-NIU
uvCNV, UMO
iCare RGC
Glaucoma
Production
AMD = Age-Related Macular Degeneration
CNV = Choroidal Neovascularization
DME = Diabetic Macular Edema
DMR = Diabetic Macular Retinopathy
PCV = Polypoidal Choroidal Vasculopathy
RVO = Retinal Vein Occlusion
UMO = Uveitic Macular Oedema
AMD = Age-Related Macular Degeneration
CNV = Choroidal Neovascularization
DME = Diabetic Macular Edema
DMR = Diabetic Macular Retinopathy
PCV = Polypoidal Choroidal Vasculopathy
RVO= Retinal Vein Occlusion
